Calculated cancer risks for polycyclic aromatic hydrocarbon mixtures in mainstream smoke of cigarettes sold in China

Bo Gao,Shexia Ma,Wei Zhao,Mi Tian,Yumei Huang,Laiguo Chen,Zhou Zhang,Zhiqiang Zhong
DOI: https://doi.org/10.1016/j.yrtph.2023.105427
IF: 3.598
2023-08-01
Regulatory Toxicology and Pharmacology
Abstract:China is the world's largest consumer of cigarettes. However, the potential cancer risk posed by polycyclic aromatic hydrocarbons (PAHs) in mainstream cigarette smoke, especially species other than benzo[a]pyrene (BaP) remains unclear. In this study, we collected yield data on multiple PAH species from a variety of cigarettes in the China market and calculated their smoking-related incremental lifetime cancer risk (ILCR) values. The computed ILCRs of the total PAHs (ILCR<sup>ΣPAHs</sup>) for ≥95% of the brands were one order of magnitude higher than the acceptable level. ILCR<sup>BaP</sup> accounted for only 5.0%-37.7% of ILCR<sup>ΣPAHs</sup> among brands, indicating that using single analyte BaP to represent ΣPAHs would significantly underestimate ILCR<sup>ΣPAHs</sup>. No clear trend of changes in ILCR<sup>ΣPAHs</sup> was found for Chinese cigarettes over multiple years, suggesting that smoking cessation is still the best option to minimize the cancer risk of PAHs. The comparison study showed that rarely reported PAHs from Chinese cigarettes can contribute over half of ILCR<sup>ΣPAHs</sup> for several American cigarettes, highlighting the imperativeness to improve the diversity of analytes for Chinese cigarettes. Adults would need to inhale the air-borne PAHs with a BaP equivalent concentration of at least 53.1 ng/m<sup>3</sup> to reach the ILCR value comparable to that obtained from smoking.
pharmacology & pharmacy,toxicology,medicine, legal
What problem does this paper attempt to address?